Caterina Viscomi

506 total citations
11 papers, 426 citations indexed

About

Caterina Viscomi is a scholar working on Molecular Biology, Oncology and Infectious Diseases. According to data from OpenAlex, Caterina Viscomi has authored 11 papers receiving a total of 426 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Oncology and 1 paper in Infectious Diseases. Recurrent topics in Caterina Viscomi's work include PI3K/AKT/mTOR signaling in cancer (3 papers), Bone health and treatments (2 papers) and HER2/EGFR in Cancer Research (2 papers). Caterina Viscomi is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (3 papers), Bone health and treatments (2 papers) and HER2/EGFR in Cancer Research (2 papers). Caterina Viscomi collaborates with scholars based in Italy, United States and Germany. Caterina Viscomi's co-authors include Michele Caraglia, Pierfrancesco Tassone, Salvatore Venuta, Pierosandro Tagliaferri, Anna Maria D’Alessandro, Alfredo Budillon, A. Abbruzzese, Alberto Abbruzzese, Monica Marra and C. Richard Boland and has published in prestigious journals such as Oncogene, British Journal of Cancer and Cell Death and Differentiation.

In The Last Decade

Caterina Viscomi

11 papers receiving 418 citations

Peers

Countries citing papers authored by Caterina Viscomi

Since Specialization

Citations

This map shows the geographic impact of Caterina Viscomi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Caterina Viscomi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Caterina Viscomi more than expected).

Fields of papers citing papers by Caterina Viscomi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Caterina Viscomi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Caterina Viscomi. The network helps show where Caterina Viscomi may publish in the future.

Co-authorship network of co-authors of Caterina Viscomi

This figure shows the co-authorship network connecting the top 25 collaborators of Caterina Viscomi. A scholar is included among the top collaborators of Caterina Viscomi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Caterina Viscomi. Caterina Viscomi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Adherence with infection prevention and control measures among Italian healthcare workers: Lessons from the COVID-19 pandemic to tackle future ones 2023 ·Journal of Infection and Public Health ·Francesca Licata, Caterina Viscomi, (unknown), Gianfranco Di Gennaro, Aida Bianco	3
2	Target Therapy in Platinum-Refractory/Resistant Ovarian Cancer: From Preclinical Findings to Current Clinical Practice 2013 ·Journal of Cancer Therapy ·Nicoletta Staropoli, Cirino Botta, Domenico Ciliberto, (unknown), (unknown), Caterina Viscomi, S Gualtieri, (unknown), Pierfrancesco Tassone, Pierosandro Tagliaferri	1
3	Advanced adult esthesioneuroblastoma successfully treated with cisplatin and etoposide alternated with doxorubicin, ifosfamide and vincristine 2009 ·Journal of Neuro-Oncology ·(unknown), (unknown), (unknown), R. Biamonte, (unknown), (unknown), (unknown), Serafino Conforti, (unknown), (unknown), Caterina Viscomi, (unknown), Salvatore Palazzo	14
4	In vivo anti‐myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor 2008 ·British Journal of Haematology ·Paola Neri, Pierosandro Tagliaferri, Maria Teresa Di Martino, Teresa Calimeri, Nicola Amodio, Alessandra Bulotta, (unknown), (unknown), Caterina Viscomi, Mariamena Arbitrio, Marco Rossi, Michele Caraglia, Nikhil C. Munshi, Kenneth C. Anderson, Pierfrancesco Tassone	56
5	Preferences of Patients with Advanced Colorectal Cancer for Treatment with Oral or Intravenous Chemotherapy 2008 ·Patient ·(unknown), Caterina Viscomi, (unknown), (unknown), (unknown), Gennaro Gadaleta‐Caldarola, Stefania Infusino, (unknown), (unknown), Claudia Sandomenico, (unknown), (unknown), (unknown), (unknown), (unknown), Salvatore Palazzo	10
6	C-Raf antagonizes apoptosis induced by IFN-α in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A 2007 ·Cell Death and Differentiation ·Annalisa Lamberti, Olimpia Longo, Monica Marra, Pierosandro Tagliaferri, Ettore Bismuto, (unknown), Caterina Viscomi, Alfredo Budillon, Ulf R. Rapp, (unknown), Salvatore Venuta, A. Abbruzzese, Paolo Arcari, Michele Caraglia	46
7	The farnesyltransferase inhibitor R115777 (ZARNESTRA®) enhances the pro‐apoptotic activity of interferon‐α through the inhibition of multiple survival pathways 2007 ·International Journal of Cancer ·Michele Caraglia, Monica Marra, Caterina Viscomi, Anna Maria D’Alessandro, Alfredo Budillon, (unknown), Claudio Arra, Antônio Barbieri, Ulf R. Rapp, Alfonso Baldi, Pierfrancesco Tassone, Salvatore Venuta, Alberto Abbruzzese, Pierosandro Tagliaferri	19
8	Antitumor Therapeutic Strategies Based on the Targeting of Epidermal Growth Factor-Induced Survival Pathways 2005 ·Current Drug Targets ·Pierosandro Tagliaferri, Pierfrancesco Tassone, Simona Blotta, Caterina Viscomi, Francesco Grillone, Alfredo Budillon, Michele Caraglia, Salvatore Venuta	12
9	The farnesyl transferase inhibitor R115777 (Zarnestra®) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa®) and Pamidronate 2004 ·Oncogene ·Michele Caraglia, Anna Maria D’Alessandro, Monica Marra, G. Giuberti, Giovanni Vitale, Caterina Viscomi, Annamaria Colao, Salvatore Del Prete, Pierosandro Tagliaferri, Pierfrancesco Tassone, Alfredo Budillon, Salvatore Venuta, Alberto Abbruzzese	65
10	New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-?) treatment of human cancer 2004 ·Cancer Immunology Immunotherapy ·Pierosandro Tagliaferri, Michele Caraglia, Alfredo Budillon, Monica Marra, Giovanni Vitale, Caterina Viscomi, Serena Masciari, Pierfrancesco Tassone, Alberto Abbruzzese, Salvatore Venuta	69
11	Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro 2003 ·British Journal of Cancer ·Pierfrancesco Tassone, Pierosandro Tagliaferri, Caterina Viscomi, Camillo Palmieri, Michele Caraglia, Anna Maria D’Alessandro, Eulalia Galea, Ajay Goel, A. Abbruzzese, C. Richard Boland, Salvatore Venuta	131

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact